bioinfor

Immunobiology and pathogenesis of hepatitis B virus infection

 

Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to trigger a persistent an infection, in the end resulting in cirrhosis and hepatocellular carcinoma.

Over the previous 4 many years, the fundamental ideas of HBV gene expression and replication in addition to the viral and host determinants governing an infection end result have been largely uncovered. Whereas HBV seems to induce little or no innate immune activation, the adaptive immune response mediates each viral clearance in addition to liver illness.

Right here, we assessment our present data on the immunobiology and pathogenesis of HBV an infection, focusing specifically on the position of CD8+ T cells and on a number of current breakthroughs that problem present dogmas.

For instance, we now belief that HBV integration into the host genome usually serves as a related supply of hepatitis B floor antigen (HBsAg) expression throughout continual an infection, presumably triggering dysfunctional T cell responses and favouring detrimental immunopathology.

Additional, the distinctive haemodynamics and anatomy of the liver – and the modifications they regularly endure throughout illness development to liver fibrosis and cirrhosis – profoundly affect T cell priming, differentiation and performance.

We additionally focus on why therapeutic approaches that restrict the intrahepatic inflammatory processes triggered by HBV-specific T cells is likely to be surprisingly useful for sufferers with continual an infection.

Schistosomes within the Lung: Immunobiology and Alternative

Schistosome an infection is a significant trigger of world morbidity, significantly in sub-Saharan Africa. Nonetheless, there is no such thing as a efficient vaccine for this main uncared for tropical illness, and re-infection routinely happens after chemotherapeutic therapy. Following invasion via the pores and skin, larval schistosomula enter the circulatory system and migrate via the lung earlier than maturing to maturity within the mesenteric or urogenital vasculature.

 

Eggs launched from grownup worms can turn into trapped in numerous tissues, with resultant inflammatory responses resulting in hepato-splenic, intestinal, or urogenital illness – processes which have been extensively studied lately.

 

In distinction, though lung pathology can happen in each the acute and continual phases of schistosomiasis, the mechanisms underlying pulmonary illness are significantly poorly understood. In continual an infection, egg-mediated fibrosis and vascular destruction can result in the formation of portosystemic shunts via which eggs can embolise to the lungs, the place they will set off granulomatous illness.

 

Acute schistosomiasis, or Katayama syndrome, which is primarily evident in non-endemic people, happens throughout pulmonary larval migration, maturation, and preliminary egg-production, usually involving fever and a cough with an accompanying immune cell infiltrate into the lung. Importantly, lung migrating larvae will not be only a reason behind irritation and pathology however are a key goal for future vaccine design.

 

Nonetheless, vaccine efforts are hindered by a restricted understanding of what constitutes a protecting immune response to larvae. On this assessment, we discover the present understanding of pulmonary immune responses and inflammatory pathology in schistosomiasis, highlighting necessary unanswered questions and areas for future analysis.

 

bioinfor
bioinfor

Immunobiology and nanotherapeutics of extreme acute respiratory syndrome 2 (SARS-CoV-2): a present replace

The emergence of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes essentially the most important international public well being problem in a century. It has reignited analysis curiosity in coronavirus.

 

  • Whereas little data is out there, analysis is at the moment in progress to comprehensively perceive the final biology and immune response mechanism in opposition to SARS-CoV-2. The spike proteins (S protein) of SARS-CoV-2 carry out a vital operate in viral an infection institution. ACE2 and TMPRSS2 play a pivotal position in viral entry. “
  • Upon viral entry, the launched pro-inflammatory proteins (cytokines and chemokines) trigger the migration of the T cells, monocytes, and macrophages to the an infection website.
  • IFNϒ launched by T cells initiates a loop of pro-inflammatory suggestions. The inflammatory state might additional improve with a rise in immune dysfunction liable for the an infection’s development.
  • A therapy strategy that stops ACE2-mediated viral entry and reduces inflammatory response is a vital therapeutic intervention technique, and nanomaterials and their conjugates are promising candidates. Nanoparticles can inhibit viral entry and replication.
  • Nanomaterials have additionally discovered utility in focused drug supply and likewise in growing a vaccine in opposition to SARS-CoV-2. Right here, we briefly summarize the origin, transmission, and medical options of SARS-CoV-2. We then mentioned the immune response mechanisms of SARS-CoV-2.
  • Lastly, we additional mentioned nanotechnology’s potentials as an intervention technique in opposition to SARS-CoV-2 an infection. All these understandings will likely be essential in growing therapeutic methods in opposition to SARS-CoV-2.

PD-1 immunobiology in glomerulonephritis and renal cell carcinoma

Background: Programmed cell demise protein (PD)-1 receptors and ligands on immune cells and kidney parenchymal cells assist preserve immunological homeostasis within the kidney. Dysregulated PD-1:PD-L1 binding interactions happen throughout the pathogenesis of glomerulopathies and renal cell carcinoma (RCC). The regulation of those molecules within the kidney is necessary to PD-1/PD-L1 immunotherapies that deal with RCC and should induce glomerulopathies as an opposed occasion.

Strategies: The expression and performance of PD-1 molecules on immune and kidney parenchymal cells had been reviewed within the wholesome kidney, PD-1 immunotherapy-induced nephrotoxicity, glomerulopathies and RCC.

Outcomes: PD-1 and/or its ligands are expressed on kidney macrophages, dendritic cells, lymphocytes, and renal proximal tubule epithelial cells. Vitamin D3, glutathione and AMP-activated protein kinase (AMPK) regulate hypoxic cell indicators concerned within the expression and performance of PD-1 molecules.

These pathways are altered in kidney illness and are linked to the manufacturing of vascular endothelial development issue, erythropoietin, adiponectin, interleukin (IL)-18, IL-23, and chemokines that bind CXCR3, CXCR4, and/or CXCR7.

These components are differentially produced in glomerulonephritis and RCC and could also be necessary biomarkers in sufferers that obtain PD-1 therapies and/or develop glomerulonephritis as an opposed occasion CONCLUSION: By evaluating the capabilities of the PD-1 axis in glomerulopathies and RCC, we recognized related chemokines concerned within the recruitment of immune cells and distinct mediators in T cell differentiation.

 

The expression and performance of PD-1 and PD-1 ligands in diseased tissue and significantly on double-negative T cells and parenchymal kidney cells wants continued exploration. The doable regulation of the PD-1 axis by vitamin D3, glutathione and/or AMPK cell indicators could also be necessary to kidney illness and the PD-1 immunotherapeutic response.

cDNA from Human Tumor Cell Line: MCF 7

C1255830 40 reactions
EUR 376
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes.

Human Mcf-7 Whole Cell Lysate

LYSATE0024 200ug
EUR 150
Description: This cell lysate is prepared from human mcf-7 using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C.

MCF-7 Nuclear Extract

X12002 1000 µg Ask for price
Description: The best epigenetics products

MCF 7 Membrane Lysate

XBL-10442 0.1 mg
EUR 516.5
Description: MCF 7 (Human breast Adenocarcinima) cell membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The MCF 7 (Human breast Adenocarcinima) cell was frozen in liquid nitrogen immediately after excision and then stored at -70ºC. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated MCF 7 (Human breast Adenocarcinima) cell membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated MCF 7 (Human breast Adenocarcinima) cell membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Genomic DNA from Human Tumor Cell Line: MCF 7

D1255830 100 ug
EUR 243
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes.

Total Protein from Human Tumor Cell Line: MCF 7

P1255830 1 mg
EUR 214
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation.

Membrane Protein from Human Tumor Cell Line: MCF 7

P3255830 0.1 mg
EUR 285
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation.

Total RNA from Human Tumor Cell Line: MCF 7

R1255830-50 50 ug
EUR 194
Description: Can be used for various studies in the realm of gene expression and regulation, both normal and pathological. It is an excellent control and suitable for educational purposes.

Paraffin Tissue Section - Human Tumor Cell Line: MCF-7

T2255830 5 slides
EUR 257
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

MCF-7 Nuclear Extract (H2O2)

1642-100
EUR 207

Human AsPC1 / Luciferase Cell Line

SC062-Luc 2 x 106 cell/ml x 1ml
EUR 1500
Description: Firefly luciferase expression stable cell line in Human AsPC1 cells with Puromycin resistance

mouse MOPC315 / Luciferase Cell Line

SC063-Luc 2 x 106 cell/ml x 1ml
EUR 2225
Description: Firefly luciferase expression stable cell line in mouse MOPC315 cells with Puromycin resistance

Human MCF-7 (breast cancer) Cell Nuclear Extract

HCL-2016 100ug
EUR 213

A549 / Luciferase (Puromycin) stable cell line

SC043-Luc 2 x 106 cell/ml x 1ml
EUR 920
Description: Luciferase (firefry) expression stable cell line in A549 human cancer cell line with Puromycin marker.

Human PANC-1 / Luciferase (Puro) Cell Line

SC068-Luc 2 x 106 cell/ml x 1ml
EUR 2225
Description: Firefly luciferase expression stable cell line in Human PANC-1 cells with Puromycin resistance

MCF-7 Whole Cell Lysate (Human breast adenocarcinoma cells)

MCF7-100 100 ug
EUR 164

MCF-7 Whole Cell Lysate (Human breast adenocarcinoma cells)

MCF7-50 50 ug
EUR 128

MCF-7 Human breast cancer, noninvasive cell line: >1x10^10 frozen exosomes

EXOP-100A-1 50 ug
EUR 467

AAV2-Luc Control Virus

AAV-320 50 ?L
EUR 1018
Description: Luciferase control virus of AAV serotype 2.

AAV1-Luc Control Virus

AAV-321 50 ?L
EUR 1018
Description: Luciferase control virus of AAV serotype 1.

AAV3-Luc Control Virus

AAV-323 50 ?L
EUR 1018
Description: Luciferase control virus of AAV serotype 3.

AAV4-Luc Control Virus

AAV-324 50 ?L
EUR 1018
Description: Luciferase control virus of AAV serotype 4.

AAV5-Luc Control Virus

AAV-325 50 ?L
EUR 1018
Description: Luciferase control virus of AAV serotype 5.

AAV6-Luc Control Virus

AAV-326 50 ?L
EUR 1018
Description: Luciferase control virus of AAV serotype 6.

MCF-10A

C0006015 One Frozen vial
EUR 467

Human MCF-7 (breast cancer) Whole Cell Lysate, Hydrogen Peroxide Stimulated

HCL-2014 100ug
EUR 213

293RTV Cell Line

RV-100 1 vial
EUR 508
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area.

293LTV Cell Line

LTV-100 1 vial
EUR 508
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area.

293AAV Cell Line

AAV-100 1 vial
EUR 508
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area.

293AD Cell Line

AD-100 1 vial
EUR 461
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area.

293/GFP Cell Line

AKR-200 1 vial
EUR 572
Description: 293/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

T47D/GFP Cell Line

AKR-208 1 vial
EUR 572
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

A549/GFP Cell Line

AKR-209 1 vial
EUR 572
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

HeLa/GFP Cell Line

AKR-213 1 vial
EUR 572
Description: HeLa/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

NIH3T3/GFP Cell Line

AKR-214 1 vial
EUR 572
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

NIH3T3/Cas9 Cell Line

AKR-5104 1 vial
EUR 572

293/Cas9 Cell Line

AKR-5110 1 vial
EUR 572

HeLa/Cas9 Cell Line

AKR-5111 1 vial
EUR 572

OVCAR-5/RFP Cell Line

AKR-254 1 vial
EUR 572
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line.

NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line

TR860A-1 >2 x 10^6 cells
EUR 3263

Platinum-E Retroviral Packaging Cell Line, Ecotropic

RV-101 1 vial
EUR 920
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-E cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection.

Platinum-A Retroviral Packaging Cell Line, Amphotropic

RV-102 1 vial
EUR 920
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-A cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection.

Platinum-GP Retroviral Packaging Cell Line, Pantropic

RV-103 1 vial
EUR 920
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-GP cells contain the gag and pol genes required for retroviral packaging; an expression vector is co-transfected with a VSVG envelope vector.

Total Protein - Murine Embryonic Stem Cell Line D3

CBA-305 500 ?g
EUR 345
Description:
  • Isolated from mouse ES-D3 cell line
  • Presented as 500 µg at 1 mg/mL in NP-40 Solubilization Buffer

Anti-Cytokeratin 7

DB051RTU-7 7 ml
EUR 204
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

pMR-Luc

PVT14074 2 ug
EUR 703

pT7- Luc

PVT10670 2 ug
EUR 301

pSBE- Luc

PVT10816 2 ug
EUR 301

pTRE3G- LUC

PVT10818 2 ug
EUR 301

pAP1- Luc

PVT10819 2 ug
EUR 301

pHSE- Luc

PVT10820 2 ug
EUR 266

pGRE- luc

PVT10821 2 ug
EUR 266

pCRE- Luc

PVT10825 2 ug
EUR 301

pViperin- Luc

PVT10826 2 ug
EUR 301

pTA- Luc

PVT10827 2 ug
EUR 301

pTAL- Luc

PVT10829 2 ug
EUR 301

pIRF3- Luc

PVT10830 2 ug
EUR 301

p53- Luc

PVT10836 2 ug
EUR 266

pBV-Luc

PVT12245 2 ug
EUR 703

Recombinant Human Galectin-7

7-00442 2µg Ask for price

Recombinant Human Galectin-7

7-00443 10µg Ask for price

Recombinant Human Galectin-7

7-00444 1mg Ask for price

Recombinant Human Interleukin-7

7-00895 2µg Ask for price

Recombinant Human Interleukin-7

7-00896 10µg Ask for price

Recombinant Human Interleukin-7

7-00897 1mg Ask for price

Recombinant Mouse Interleukin-7

7-00904 2µg Ask for price

Recombinant Mouse Interleukin-7

7-00905 10µg Ask for price

Recombinant Mouse Interleukin-7

7-00906 1mg Ask for price

Recombinant Human Kallikrein-7

7-03034 2µg Ask for price

Recombinant Human Kallikrein-7

7-03035 10µg Ask for price

Recombinant Human Kallikrein-7

7-03036 100µg Ask for price

Recombinant ProMatrix Metalloproteinase-7

7-03478 5µg Ask for price

Recombinant ProMatrix Metalloproteinase-7

7-03479 20µg Ask for price

Recombinant ProMatrix Metalloproteinase-7

7-03480 1mg Ask for price

Individual Reaction Mix 7

G065-7 200 reactions
EUR 167

Huamn SW403 / Luciferase Stable Cells

SC067-Luc 2 x 106 cell/ml x 1ml
EUR 1500
Description: Firefly luciferase expression stable cell line in human SW403 cells with Puromycin resistance

β-Lactamase (Luciferase) lentiviral particles

LVP335-luc 1x107 IFU/ml x 200ul
EUR 349
Description: pre-made lentiviral particles expressing β-Lactamase gene. A firefly luciferase marker was expressed under RSV promoter. Particles is provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

Recombinant Human Interleukin-7, Saccharomyces

7-00898 2µg Ask for price

Recombinant Human Interleukin-7, Saccharomyces

7-00899 10µg Ask for price

Recombinant Human Interleukin-7, Saccharomyces

7-00900 1mg Ask for price

Recombinant Human Matrix Metalloproteinase-7

7-03154 5µg Ask for price

Recombinant Human Matrix Metalloproteinase-7

7-03155 20µg Ask for price

Recombinant Human Matrix Metalloproteinase-7

7-03156 1mg Ask for price

Lung Lysate (7 Days Old)

1402-7 0.1 mg
EUR 191
Description: Lung tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Brain Lysate (7 Days Old)

1403-7 0.1 mg
EUR 191
Description: Brain tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Liver Lysate (7 Days Old)

1404-7 0.1 mg
EUR 191
Description: Liver tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Kidney Lysate (7 Days Old)

1405-7 0.1 mg
EUR 191
Description: Kidney tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Spleen Lysate (7 Days Old)

1406-7 0.1 mg
EUR 191
Description: Spleen tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Thymus Lysate (7 Days Old)

1409-7 0.1 mg
EUR 191
Description: Thymus tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Stomach Lysate (7 Day Old)

1415-7 0.1 mg
EUR 191
Description: Stomach tissue lysate (7 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Skin Lysate (7 Days Old)

1419-7 0.1 mg
EUR 191
Description: Skin tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Eye Lysate (7 Days Old)

1420-7 0.1 mg
EUR 191
Description: Eye tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

p21-Luc Plasmid

PVTB00035-2c 2 ug
EUR 356

pGL3-ELAM-Luc

PVT14533 2 ug
EUR 599

proE-cad178-Luc

PVT14614 2 ug
EUR 599

pSynSRE-T-Luc

PVT14626 2 ug
EUR 703

pUC57-Tac-Luc

PVT18215 2 ug
EUR 258

IgK- IFN- luc

PVT10425 2 ug
EUR 266

pNFAT- TA- Luc

PVT10808 2 ug
EUR 266